Scott S Tykodi1, John A Thompson. 1. Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Mailstop G4-830, Seattle, WA 98109-1023, USA.
Abstract
BACKGROUND: The tumor-associated antigen 5T4 is expressed on a high percentage of human carcinomas and has limited expression in normal tissues. A recombinant pox virus vector expressing this antigen, modified vaccinia Ankara (MVA)-5T4, has been tested as a cancer vaccine. OBJECTIVE: Treatment with MVA-5T4 has been studied both as a single agent and in combination with standard chemo-, biologic- or targeted-therapies in patients with advanced colorectal cancer, renal cell carcinoma (RCC) or hormone-refractory prostate cancer. METHODS: This review summarizes data from clinical studies with MVA-5T4 reported in published manuscripts, meeting abstracts or posted on websites relevant to clinical trials or MVA-5T4. RESULTS/ CONCLUSION: Vaccination with MVA-5T4 is well tolerated and elicits 5T4-specific humoral and/or cellular responses in most of the treated patients. Retrospective analyses of Phase II studies have suggested a positive association between immune responses to 5T4 and favorable clinical outcomes. A continuing Phase III, double-blind, placebo-controlled trial seeks to confirm a positive association between vaccination with MVA-5T4 and survival in patients with advanced RCC.
BACKGROUND: The tumor-associated antigen 5T4 is expressed on a high percentage of humancarcinomas and has limited expression in normal tissues. A recombinant pox virus vector expressing this antigen, modifiedvaccinia Ankara (MVA)-5T4, has been tested as a cancer vaccine. OBJECTIVE: Treatment with MVA-5T4 has been studied both as a single agent and in combination with standard chemo-, biologic- or targeted-therapies in patients with advanced colorectal cancer, renal cell carcinoma (RCC) or hormone-refractory prostate cancer. METHODS: This review summarizes data from clinical studies with MVA-5T4 reported in published manuscripts, meeting abstracts or posted on websites relevant to clinical trials or MVA-5T4. RESULTS/ CONCLUSION: Vaccination with MVA-5T4 is well tolerated and elicits 5T4-specific humoral and/or cellular responses in most of the treated patients. Retrospective analyses of Phase II studies have suggested a positive association between immune responses to 5T4 and favorable clinical outcomes. A continuing Phase III, double-blind, placebo-controlled trial seeks to confirm a positive association between vaccination with MVA-5T4 and survival in patients with advanced RCC.
Authors: Kate Mulryan; Matthew G Ryan; Kevin A Myers; David Shaw; Who Wang; Susan M Kingsman; Peter L Stern; Miles W Carroll Journal: Mol Cancer Ther Date: 2002-10 Impact factor: 6.261
Authors: E. Wrigley; A.T. McGown; J. Rennison; R. Swindell; D. Crowther; T. Starzynska; P.L. Stern Journal: Int J Gynecol Cancer Date: 1995-07 Impact factor: 3.437
Authors: Dirk Nagorsen; Carmen Scheibenbogen; Francesco M Marincola; Anne Letsch; Ulrich Keilholz Journal: Clin Cancer Res Date: 2003-10-01 Impact factor: 12.531
Authors: T Starzynska; A Wiechowska-Kozlowska; K Marlicz; M Bromley; S A Roberts; M Lawniczak; B Kolodziej; A Zyluk; P L Stern Journal: Eur J Gastroenterol Hepatol Date: 1998-06 Impact factor: 2.566
Authors: Khoon Lin Ling; Sarah E Pratap; Gaynor J Bates; Baljit Singh; Neil J Mortensen; Bruce D George; Bryan F Warren; Juan Piris; Giovanna Roncador; Stephen B Fox; Alison H Banham; Vincenzo Cerundolo Journal: Cancer Immun Date: 2007-03-28
Authors: Scott S Tykodi; Shoko Satoh; Janise D Deming; Jeffrey Chou; Richard Harrop; Edus H Warren Journal: J Immunother Date: 2012-09 Impact factor: 4.456
Authors: Stephen R Walsh; Marissa B Wilck; David J Dominguez; Elise Zablowsky; Shringkhala Bajimaya; Lisa S Gagne; Kelly A Verrill; Jane A Kleinjan; Alka Patel; Ying Zhang; Heather Hill; Aruna Acharyya; David C Fisher; Joseph H Antin; Michael S Seaman; Raphael Dolin; Lindsey R Baden Journal: J Infect Dis Date: 2013-03-12 Impact factor: 5.226
Authors: Birgit Schäfer; Georg W Holzer; Alexandra Joachimsthaler; Sogue Coulibaly; Michael Schwendinger; Brian A Crowe; Thomas R Kreil; P Noel Barrett; Falko G Falkner Journal: PLoS One Date: 2011-09-09 Impact factor: 3.240
Authors: Guang-Yun Song; Tumul Srivastava; Hidenobu Ishizaki; Simon F Lacey; Don J Diamond; Joshua D I Ellenhorn Journal: Cancer Invest Date: 2011-08-15 Impact factor: 2.176